Sight Sciences (NasdaqGS:SGHT) 2026 Conference May 13, 2026 06:15 PM ET Company Participants Our label allows us to educate on all of these benefits of OMNI in combo cataract, both mild, moderate, and severe, as well as standalone, mild, moderate, and severe. They're all significant opportunities today. Most of MIGS is done in combination with cataract. You see the that mild to moderate combo cataract, about a $4 billion opportunity. There's an opportunity for expanding that combo cataract market the standa ...